Literature DB >> 36268524

Re-exposure with a TNF inhibitor bio-similar was well tolerated and led to sustained control of psoriatic arthritis after allergic reaction to the TNF inhibitor bio-originator.

Larissa Valor-Méndez1,2, Carla Dorn3, Bernhard Manger1,2, Georg Schett1,2, Arnd Kleyer1,2.   

Abstract

Entities:  

Year:  2022        PMID： 36268524      PMCID： PMC9575662          DOI： 10.1093/rap/rkac079

Source DB:  PubMed          Journal:  Rheumatol Adv Pract        ISSN： 2514-1775


× No keyword cloud information.
  8 in total

Review 1.  Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.

Authors:  Robert J Moots; Cinzia Curiale; Danielle Petersel; Catherine Rolland; Heather Jones; Eduardo Mysler
Journal:  BioDrugs       Date:  2018-06       Impact factor: 5.807

2.  Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.

Authors:  Kristin K Jørgensen; Inge C Olsen; Guro L Goll; Merete Lorentzen; Nils Bolstad; Espen A Haavardsholm; Knut E A Lundin; Cato Mørk; Jørgen Jahnsen; Tore K Kvien
Journal:  Lancet       Date:  2017-05-11       Impact factor: 79.321

Review 3.  Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis.

Authors:  Kelly A Reynolds; Deeti J Pithadia; Erica B Lee; Wilson Liao; Jashin J Wu
Journal:  Am J Clin Dermatol       Date:  2020-08       Impact factor: 7.403

Review 4.  Infliximab-Related Infusion Reactions: Systematic Review.

Authors:  Lev Lichtenstein; Yulia Ron; Shmuel Kivity; Shomron Ben-Horin; Eran Israeli; Gerald M Fraser; Iris Dotan; Yehuda Chowers; Ronit Confino-Cohen; Batia Weiss
Journal:  J Crohns Colitis       Date:  2015-06-19       Impact factor: 9.071

Review 5.  Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective.

Authors:  Ágnes Milassin; Anna Fábián; Tamás Molnár
Journal:  Therap Adv Gastroenterol       Date:  2019-04-15       Impact factor: 4.409

Review 6.  Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents.

Authors:  Vibeke Strand; Joao Gonçalves; Timothy P Hickling; Heather E Jones; Lisa Marshall; John D Isaacs
Journal:  BioDrugs       Date:  2020-02       Impact factor: 5.807

7.  Regulatory eosinophils induce the resolution of experimental arthritis and appear in remission state of human rheumatoid arthritis.

Authors:  Darja Andreev; Mengdan Liu; Katerina Kachler; Mireia Llerins Perez; Philipp Kirchner; Julia Kölle; Andreas Gießl; Simon Rauber; Rui Song; Oliver Aust; Anika Grüneboom; Arnd Kleyer; Juan D Cañete; Arif Ekici; Andreas Ramming; Susetta Finotto; Georg Schett; Aline Bozec
Journal:  Ann Rheum Dis       Date:  2020-11-04       Impact factor: 19.103

Review 8.  Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review.

Authors:  Ross A McKinnon; Matthew Cook; Winston Liauw; Mona Marabani; Ian C Marschner; Nicolle H Packer; Johannes B Prins
Journal:  BioDrugs       Date:  2018-02       Impact factor: 5.807
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.